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OBJECTIVES: Grass pollen induced allergic rhinoconjunctivitis (ARC) constitutes a
large burden for the society. The prevalence is increasing and up to 20% of the
European and US populations suffer from respiratory allergies including grass pol-
len induced ARC. The majority of patients are treated with symptomatic medica-
tions; however a large proportion remains uncontrolled despite the use of such
treatments. Specific immunotherapy (SIT) is the only treatment documented to
target the underlying cause of the allergic disease leading to a sustained effect after
treatment completion. The aim of this study was to compare the economic conse-
quences of treatment of patients with ARC with a grass allergy immunotherapy
tablet (AIT) and the clinical practice of subcutaneous immunotherapy (SCIT).
METHODS: A cost-minimisation analysis (CMA) was applied comparing the SQ-
standardised grass AIT (Grazax, Phleum pratense, 75,000 SQ-T/2,800 BAU, ALK,
Denmark) with SCIT (Alutard, Phleum pratense, 100,000 SQ-U/ml, ALK, Denmark).
The CMA included health care utilisation measured in physical units based on
national guidelines, literature reviews and expert opinions, as well as valuation in
unit costs based on drug tariffs, physician fee structures and wage statistics. The
CMA was conducted from a Danish societal and health care perspective. RESULTS:
Treating patients with ARC with the grass AIT instead of grass SCIT results in a
significantly reduced number of physician visits leading to a total reduction in
direct treatment costs, direct patient costs as well as in indirect costs of €3526 per
patient during a treatment course. A one-way sensitivity analysis confirmed the
robustness of these results. CONCLUSIONS: The cost minimisation analyse shows
that grass AIT is a cost-saving alternative to SCIT when treating patients suffering
from grass pollen induced ARC.
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OBJECTIVES: A budget impact analysis was conducted to estimate the impact of
Staloral Birch® on a market of selected number of relevant birch allergens.
METHODS: The hypothetical market for birch allergens consisted of 3 compounds;
Staloral Birch®, ALK Depot SQ® and SLITone®. Randomized controlled trials have
been performed to estimate safety and efficacy of Staloral Birch® and ALK Depot
SQ®; however, for SLITone® no comparable evidence-based information is avail-
able. Actual German market data from 2008-2010 served as a basis for future esti-
mates of market share development. Future predictions were made on market
uptake and market dynamics (i.e. which drug increases their market share at the
expense of another drug). German drug acquisition costs were taken from the
Lauer-Taxe; average annual treatment related costs have been extracted from a
recent cost-effectiveness analysis for grass allergens. The analysis perspective was
that of the German payer (i.e. Statutory Health Insurance). Three different scenario
analyses were conducted over a 5-year time horizon. RESULTS: The total market
budget in 2010 for these 3 therapies was estimated to be € 36,485,362. It decreased
with €2,263,694 over a 5-year period in the first scenario, when the annual uptake of
Staloral Birch® was set at 6.9% with market dynamics of 80%/20% (ALK Depot
SQ®/SLITone®). These savings represent 1.2% of the cumulative reference budget
varying from 0.4% in 2011 to 2.1% in 2015. In the second scenario market uptake for
Staloral Birch® was varied from2% to8% annually. Accordingly, the budget was
reduced by €656,143 to €2,624,573. In the final scenario, shifting market dynamics
from 90%/10% to 70%/30% (ALK Depot SQ®/SLITone ®) showed a reduction of
€136,675 to €4,390,713.CONCLUSIONS: Increasing Staloral Birch® market share was
estimated to result in a stable, if not decreasing budget with more patients treated
using an evidence-based compound.
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OBJECTIVES: To assess the economic impact of introducing beclomethasone/for-
moterol extrafine for the treatment of moderate to severe persistent asthma in six
Spanish regions including Andalusia, Bask Country, Catalonia, Galicia, Madrid and
Valencia. METHODS: A budget impact model was developed using the perspective
of the Spanish regional healthcare services with a 5-year time horizon. The model
was populated with regional data on disease prevalence, population growth, drug
tariffs, healthcare resource utilization, unit costs and market shares. Drugs con-
sidered in the study were fluticasone/salmeterol, budesonide/formoterol and be-
clomethasone/formoterol extrafine. Costs considered included drug costs, diag-
nostic tests, physician visits, hospitalisation and adverse effects treatment costs.
All costs referred to EUR 2010, using a 5% annual discount rate. Total annual health-
care costs were estimated based on mean costs per patient for each treatment
before and after the introduction of beclomethasone/formoterol extrafine.
RESULTS: Based upon the Spanish adult population data and asthma prevalence,
the treated population with moderate to severe persistent asthma in 2010 was
estimated at 110,346 in Andalusia, at 16,369 in the Bask Country, at 31,118 in Cata-
lonia, at 30,506 in Galicia, at 21,800 in Madrid and at 37,316 in Valencia versus
populations of 140,684, 19,893, 38,378, 37,753, 27,660 and 46,789 respectively in
2015. The annual mean cost per patient was €996 before the introduction of beclo-
methasone/formoterol extrafine and €990 after its introduction. Total annual
health care costs over the next 5 years for all six regions range between €95,7 and
€661,6 million for the Bask Country and Andalucia before the introduction of be-
clomethasone/formoterol extrafine and €95,1 and €657,9 million after its introduc-
tion, respectively.CONCLUSIONS:The introduction of beclomethasone/formoterol
extrafine for the treatment of moderate to severe persistent asthma showed to
reduce the budget impact for each of the regional health care services by showing
net savings for all six regions over the next 5 years.
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OBJECTIVES: Specific immunotherapy (SIT) is the only potentially curative therapy
in patients with allergic rhinitis (AR) and allergic asthma (AA). The present study
examined the effects of specific immunotherapy (SIT) on the financial situation of
the German statutory health insurance systems (SHI). METHODS: Taking popula-
tion projections of the German Statistical Federal Office, the number of expected
new cases (AR, AA) was calculated until 2050. Based on assumptions about the
proportion of patients who received SIT in the future, age cohorts passed cost-
effectiveness models that were based on Markov chains. For determining the cost
situation of SIT remedies, we used selling prices for Allergovit® depot suspensions.
All future costs are discounted at a rate of 2%. Data on effectiveness were extracted
from published literature. The model calculation was supplemented by a Delphi
panel and additional probabilistic sensitivity analysis. RESULTS: Based on the cur-
rent situation, a total annual economic burden of € 1 billion is expected for care of
patients with pollen-induced AR and AA in Germany. Several realistic scenarios
have shown, that despite higher initial expenses, savings of up to 10% of the aver-
age total annual cost are realizable. That would mainly driven by a reduced number
of patients suffering from AA. The size of this cost reduction is mainly affected by
the starting point of therapy: If SIT is applied at an early disease stage without
asthma symptoms, the expected number of asthma sufferers is up to 35% lower
compared to status quo. CONCLUSIONS: From the perspective of statutory health
insurance companies, SIT could be a useful strategic option to prevent future al-
lergic disease cases and to reduce associated medical expenses.
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OBJECTIVES:To estimate the budget impact of introducing indacaterol in the treat-
ment of COPD over a 5-year time horizon in patients eligible for treatment with
long-acting maintenance therapy. METHODS: An Excel-based budget impact
model was developed to calculate the budget impact based on local epidemiologi-
cal and drug costs data. The number of patients eligible for treatment with long-
acting maintenance therapy was estimated considering: 1) the local adult popula-
tion (40 years old) of approximately 14.5 millions; 2) proportion of population
using the public healthcare system services and medications around 77%; 3) prev-
alence of local COPD patients about 15.8%; 4) 18% of these patients are diagnosed
and receiving treatment; 5) 1.05% of annual population growth rate; 6) the same
patient distribution in each disease severity across all years was assumed as 64% of
mild, 29% of moderate, 6% of severe and 1% of very severe; 7) only patients in
moderate, severe and very severe groups were considered as eligible for treatment
with long-acting maintenance therapy; and 8) 53% of annual treatment persistence
rate was applied. The ex-factory price with 24.38% of discount was used for inda-
caterol costs and 5% of annual discount rate was applied on the costs. Indacaterol
150g uptake was assumed to be: 10%, 15%, 20%, 23%, 25%, over 5 years
consecutively. RESULTS: The number of patients eligible for treatment with long-
acting maintenance therapy in São Paulo was estimated to be around 60,754 in the
first year. The annual net budget impact of indacaterol was negative through the
years around: -88K, -1.7M, -3.2M, -4.2M and -4.4M (BRL) consecutively.
CONCLUSIONS: The budget impact results show that indacaterol has potential to
reduce costs on the budget of State health care system.
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OBJECTIVES:To estimate the budget impact of introducing indacaterol in the treat-
ment of COPD over a 5-year time horizon in patients eligible for treatment with
long-acting maintenance therapy. METHODS: An Excel-based budget impact
model was developed to calculate the budget impact based on local epidemiologi-
cal and drug costs data. The number of patients eligible for treatment with long-
acting maintenance therapy was estimated considering: 1) the local adult popula-
tion (40 years old) of approximately 61 millions; 2) proportion of population using
the public healthcare system services and medications around 77%; 3) prevalence
of local COPD patients about 15.8%; 4) 18% of these patients are diagnosed and
receiving treatment; 5) 1.05% of annual population growth rate; 6) the same patient
distribution in each disease severity across all years was assumed as 64% of mild,
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